Recent News

• 03.04.2025 - Femasys Offers a Fresh Take on Women’s Reproductive Healthcare
• 01.30.2025 - Disrupting Stagnant Women’s Reproductive Health Ecosystem with Safer More Accessible Options with Kathy Lee-Sepsick Femasys
• 01.30.2025 - Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
• 11.26.2024 - Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
• 11.21.2024 - Innovation in Women’s Reproductive Health is More Important than Ever
• 11.21.2024 - Innovation in Women’s Reproductive Health is More Important than Ever
• 11.05.2024 - Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment

Recent Filings

• 02.26.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.26.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2024 - 8-K/A Current report
• 11.12.2024 - EX-99.1 EX-99.1
• 11.12.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2024 - 8-K Current report